We welcome your feedback and / or questions related to the
educational content provided through Mechanisms in Chronic Myelogenous Leukemia.
Release date:
November 30, 2008
Expiration date:
November 30, 2009
Click here to view Technical Requirements
Accreditation
This learning activity has been designated for 2.50 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in this activity.
Target Audience
This learning activity is intended for medical oncologists, hematologists, stem cell transplant physicians, and other interested healthcare professionals who manage and treat chronic myelogenous leukemia in the hematology/oncology and transplant patient settings.
Learning Objectives
After completing this educational activity, the learner should be better able to:
- Understand the mechanisms involved in imatinib relapse
- State the recommendations regarding early detection of suboptimal response or treatment failure in patients receiving imatinib therapy
- Discuss second-line and third-line treatment options in patients who do not respond adequately to imatinib
- Explain the issues involved in chronic myelogenous leukemia (CML) stem cell survival and its clinical significance
Author
Michael W. N. Deininger, MD, PhD
Section Head
Center for Hematologic Malignancies, Non-Transplant
Associate Professor
Department of Medicine, Division of Hematology & Medical Oncology
Oregon Health & Science University
Portland, Oregon
Medical Writers
Karla Badger-Brown, PhD
Toronto, Ontario
Laurel McKee Ranger
Randolph, New Jersey
Disclosure of Financial Interests
As an accredited provider of continuing medical education, Imedex, LLC is required to ask authors to disclose any real or apparent conflict of interest they may have as related to the content of their chapter(s). The existence of commercial or financial interests of speakers related to the subject matter of their chapter(s) should not be construed as implying bias or decreasing the value of their chapter(s). However, the disclosure should help participants form their own judgments.
All authors were independently selected by the organizing committee.
Those authors who disclosed affiliations or financial interests with the commercial organizations
involved with products, to which they may refer are listed below.
- grant research
- consultant
- speaker's bureau
- stock shareholder
- other support
Dr Michael W. N. Deininger
Supporters of this activity:
Bristol-Myers Squibb 2
Other affiliations:
Cytopia 1
Genzyme 1
Novartis 2
Medical Writers
Karla Badger-Brown, PhD
Does not report any affiliations with commercial organizations.
Laurel McKee Ranger
Does not report any affiliations with commercial organizations.
Imedex, LLC Staff Disclosure of Financial Relationships
Imedex, LLC is a subsidiary of AmerisourceBergen Specialty Group, which is a subsidiary of AmerisourceBergen Company. All Imedex staff members, except for the following, who are in a position to control the content of this activity, have no financial relationships with any commercial interests that are relevant to this activity:
Keith Steward, MD, MBA, owns shares of Pfizer Inc and Johnson & Johnson, as well as stock options for AmerisourceBergen.
Chris Bolwell owns shares of GlaxoSmithKline and stock options for AmerisourceBergen.
Bradley Bongiovanni, ND, Becky Lynch, RN, Emily Geiger, and Don Harting, MA, ELS own stock options for AmerisourceBergen.
Imedex, LLC is an independent provider of continuing medical education. Imedex, LLC has no proprietary or financial interest in medical or healthcare products over which the FDA has regulatory authority.
Disclosure of Unapproved Uses and Investigational Drugs
This activity may contain information about experimental and other uses of drugs or devices that are not currently approved by the US Food and Drug Administration (FDA) and/or other national regulatory agencies in the United States and other countries. Participants in the United States are encouraged to consult the FDA-approved product labeling for any drug or device mentioned in this program before use. Participants from other countries should consult with their respective regulatory authorities.
Statement of Commercial Support
The following company has provided an unrestricted educational grant in support of this activity: Bristol-Myers Squibb
(*Please check this box to proceed - required)
|